Jiangsu Handian Biotech lands tens of millions of yuan in strategic round

What's the deal? Jiangsu Handian BiotechDealroom has a profile for this one. Try Dealroom → has raised tens of millions of yuan in a strategic funding round, the company said in September 2026. Bailian Zhigao Capital was the sole investor.

What's the endgame? Handian Biotech plans to use the money to upgrade its research and innovation systems, build out global manufacturing bases, and develop a cross-border supply chain.

The signal: The round points to continued investor appetite for Chinese biotech firms looking to scale beyond their home market, with global production and cross-border logistics at the centre of the strategy.

Image credit: Generated with Gemini